等待开盘 06-26 09:30:00 美东时间
+1.350
+4.40%
Needham initiates MapLight with Buy, citing ML-007C-MA potential in schizophrenia and AD psychosis, with key readouts expected through 2027.
04-09 02:29
Companies Reporting Before The Bell • ProShares UltraShort Russell2000 (NYSE:TW...
03-26 19:11
MapLight Therapeutics (NASDAQ:MPLT) reported quarterly losses of $(37.18) per share which missed the analyst consensus estimate of $(1.55) by 2291 percent. This is a 48.25 percent decrease over losses of $(25.08) per
2025-12-04 21:06